A Practical Synthetic Approach to Chiral (α-Chloroalkyl)boronic Esters via Iridium-Catalyzed Chemoselective Hydrogenation of Chloro-Substituted Alkenyl Boronates

Stephen J. Roseblade; Eva Casas-Arcé; Ulrike Nettekoven; Ivana Gazić Smilović; Antonio Zanotti-Gerosa; Zdenko Časar

doi:10.1055/s-0033-1338512

Synthesis, Table of Contents

Synthesis 2013; 45(20): 2824-2831
DOI: 10.1055/s-0033-1338512

practical synthetic procedures

A Practical Synthetic Approach to Chiral (α-Chloroalkyl)boronic Esters via Iridium-Catalyzed Chemoselective Hydrogenation of Chloro-Substituted Alkenyl Boronates

Authors

Stephen J. Roseblade

^aJohnson Matthey, Catalysis and Chiral Technologies, Unit 28, Cambridge Science Park, Milton Road, Cambridge CB4 0FP, UK
Eva Casas-Arcé

^aJohnson Matthey, Catalysis and Chiral Technologies, Unit 28, Cambridge Science Park, Milton Road, Cambridge CB4 0FP, UK
Ulrike Nettekoven

^bSolvias AG, Business Unit Synthesis and Catalysis, Römerpark 2, 4303 Kaiseraugst, Switzerland
Ivana Gazić Smilović

^cLek Pharmaceuticals, d.d., Sandoz Development Center Slovenia, API Development, Organic Synthesis Department, Kolodvorska 27, 1234 Mengeš, Slovenia
Antonio Zanotti-Gerosa

^aJohnson Matthey, Catalysis and Chiral Technologies, Unit 28, Cambridge Science Park, Milton Road, Cambridge CB4 0FP, UK
Zdenko Časar*

^cLek Pharmaceuticals, d.d., Sandoz Development Center Slovenia, API Development, Organic Synthesis Department, Kolodvorska 27, 1234 Mengeš, Slovenia

^dSandoz GmbH, Global Portfolio Management API, 6250 Kundl, Austria Fax: +43(5338)200418 Email: zdenko.casar@sandoz.com

^eFaculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia

Abstract

All articles of this category

Dedicated to Prof. Dr. Dominique Lorcy (University of Rennes 1, France) on the occasion of her birthday

Abstract

Chiral (α-chloroalkyl)boronic esters are obtained by homogeneous asymmetric iridium-catalyzed chemoselective hydrogenation of (1-chloro-1-alkenyl)boronic esters. P,N–Iridium catalysis provides low level of dehalogenation during the hydrogenation, while the catalyst activity and enantioselectivity essentially depends on the applied P,N ligand features. Fine tuning of P,N ligand structures enables high conversions, broad substrate acceptance, and high to excellent enantioselectivities with enantiomeric excess values up to 94% along with low levels of dechlorination. Low catalyst loading with S/C = 200 can also be achieved for the preparation of an industrially important isobutyl derivative.

Key words

alkenes - alkyl halides - asymmetric synthesis - chemoselectivity - hydrogenation

Full Text

References

References

1a Matteson DS. Chem. Rev. 1989; 89: 1535
1b Matteson DS. Tetrahedron 1989; 45: 1859
1c Matteson DS. Tetrahedron 1998; 54: 10555

2a Yang W, Gao X, Wang B. Med. Res. Rev. 2003; 23: 346
2b Matteson DS. Med. Res. Rev. 2008; 28: 233
2c Baker SJ, Ding CZ, Akama T, Zhang Y.-K, Hernandez V, Xia Y. Future Med. Chem. 2009; 1: 1275
2d Dembitsky VM, Al Quntar AA, Srebnik M. Chem. Rev. 2011; 111: 209
2e Smoum R, Rubinstein A, Dembitsky VM, Srebnik M. Chem. Rev. 2012; 112: 4156
2f Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG. Curr. Hematol. Malig. Rep. 2012; 7: 258
2g Dick LR, Fleming PE. Drug Discovery Today 2010; 15: 243

For recent synthetic approaches to α-aminoboronic acid derivatives, see:

3a Beenen MA, An C, Ellman JA. J. Am. Chem. Soc. 2008; 130: 6910
3b Sun J, Kong L. Chin. Pat. Appl CN101812026, 2010 ; Chem. Abstr. 2010, 153, 383296
3c Solé C, Gulyás H, Fernández E. Chem. Commun. 2012; 48: 3769
3d He Z, Zajdlik A, St Denis JD, Assem N, Yudin AK. J. Am. Chem. Soc. 2012; 134: 9926
3e Zhang S.-S, Zhao Y.-S, Tian P, Lin G.-Q. Synlett 2013; 24: 437
3f Wen K, Wang H, Chen J, Zhang H, Cui X, Wei C, Fan E, Sun Z. J. Org. Chem. 2013; 78: 3405
3g Hong K, Morken JP. J. Am. Chem. Soc. 2013; 135: 9252

4a Touchet S, Carreaux F, Carboni B, Bouillon A, Boucher J.-L. Chem. Soc. Rev. 2011; 40: 3895
4b Rentsch A, Landsberg D, Brodmann T, Bülow L, Girbig A.-K, Kalesse M. Angew. Chem. Int. Ed. 2013; 52: 5450

5 Paramore A, Frantz S. Nat. Rev. Drug Discovery 2003; 2: 611

For the synthesis of Bortezomib and its building blocks, see:

6a Kettner CA, Shenvi AB. J. Biol. Chem. 1984; 259: 15106
6b Tsai DJ. S, Jesthi PK, Matteson DS. Organometallics 1983; 2: 1543
6c Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma Y.-T, Plamondon L, Stein RL. Bioorg. Med. Chem. Lett. 1998; 8: 333
6d Ivanov AS, Zhalnina AA, Shishkov SV. Tetrahedron 2009; 65: 7105

7 Cvek B. Drugs Future 2012; 37: 561

8a Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. Blood 2008; 111: 2765
8b Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, Cassarà PG, D’Arasmo G, Ferretti E, De Munari S, Oliva A, Pezzoni G, Allievi C, Strepponi I, Ruggeri B, Ator MA, Williams M, Mallamo JP. J. Med. Chem. 2008; 51: 1068

9 Johnson KM. S. Curr. Opin. Investig. Drugs 2010; 11: 455

10a Ohmura T, Awano T, Suginome M. Chem. Lett. 2009; 38: 664
10b Ohmura T, Awano T, Suginome M. J. Am. Chem. Soc. 2010; 132: 13191
10c Awano T, Ohmura T, Suginome M. J. Am. Chem. Soc. 2011; 133: 20738

11 For a review on the dehalogenation in homogeneous hydrogenations, see: Sisak A, Simon OB. In The Handbook of Homogeneous Hydrogenation . de Vries JG, Elsevier CJ. Wiley-VCH; Weinheim: 2007. Chap. 18, 513-546

12a Gazić Smilović I, Casas-Arcé E, Roseblade SJ, Nettekoven U, Zanotti-Gerosa A, Kovačevič M, Časar Z. Angew. Chem. Int. Ed. 2012; 51: 1014
12b Gazić Smilović I, Časar Z. PCT Pat. Appl WO2010146172, 2010 ; Chem. Abstr. 2010, 154, 88353.
12c Gazić Smilović I, Časar Z. PCT Pat. Appl WO2010146176, 2010 ; Chem. Abstr. 2010, 154, 88352.
12d Burgess K. Chem. Ind. 2012; 76: 52
12e Lautens M, Zhang L. Synfacts 2012; 8: 395
12f Lautens M, Petrone DA. Synfacts 2012; 8: 990
12g Bull JA. Angew. Chem. Int. Ed. 2012; 51: 8930
12h Lambert TH. Org. Chem. Highlights 2013; February 11. URL: http://www.organic-chemistry.org/Highlights/ 2013/11February.shtm

For the preparation of [Rh(cod)DiPFc]BF₄, see:

13a Tararov VI, Kadyrov R, Riermeier TH, Holz J, Borner A. Tetrahedron: Asymmetry 1999; 10: 4009
13b Nedden HG. PCT Pat. Appl WO2008084258, 2008 ; Chem. Abstr. 2008, 149, 176474.

For the synthesis and application of phosphinite-oxazoline ligands, see:

14a Blankenstein J, Pfaltz A. Angew. Chem. Int. Ed. 2001; 40: 4445
14b Menges F, Pfaltz A. Adv. Synth. Catal. 2002; 344: 40

15 For the preparation and use of PHOX ligands, see: Helmchen G, Pfaltz A. Acc. Chem. Res. 2000; 33: 336
16 For the preparation and application of SimplePHOX ligands, see: Smidt SP, Menges F, Pfaltz A. Org. Lett. 2004; 6: 2023
17 For the preparation and use of PyrPHOX ligands, see: Cozzi PG, Zimmermann N, Hilgraf R, Schaffner S, Pfaltz A. Adv. Synth. Catal. 2001; 343: 450

For the preparation of phosferrox (Fc-PHOX) type ligands, see:

18a Richards CJ, Mulvaney AW. Tetrahedron: Asymmetry 1996; 7: 1419
18b Ahn KH, Cho C.-W, Baek H.-H, Park J, Lee S. J. Org. Chem. 1996; 61: 4937

19 For the synthesis and application of NeoPHOX ligands, see: Schrems MG, Pfaltz A. Chem. Commun. 2009; 41: 6210
20 For the preparation and application of ferrocenyl-phosphinoimidazoline ligands, see: Boaz NW, Ponasik JA. Jr. US Patent Appl. US20070244319, 2007 ; Chem. Abstr. 2007, 147, 448932.
21 Engman M, Diesen JS, Paptchikhine A, Andersson PG. J. Am. Chem. Soc. 2007; 129: 4536